NPC Resources Provide Information on Panel Topics at 2016 Armada Specialty Summit

Will you be attending the 2016 Armada Specialty Pharmacy Summit in Las Vegas from May 2-6? Get prepared for the conversations and meetings on event topics with some helpful background resources, which are available on the National Pharmaceutical Council’s (NPC) website and at our exhibit booth (#633):

Value Assessment Frameworks

As part of the shift from a volume-based health system toward a value-based one, there is an increased interest in understanding how to assess the value of all aspects of health care. NPC’s most recent research reviews existing value assessment frameworks and recommends guiding practices for value assessments.

• Guiding Practices for Patient-Centered Value Assessment: This research brief and its accompanying infographic outline good practices to guide meaningful value assessments. The Guiding Practices address the assessment process; methodology; benefits; costs; evidence; and dissemination and utilization, as well as considerations for budget impact analysis.
• Current Landscape: Value Assessment Frameworks: This white paper compares and contrasts key characteristics of five value assessment frameworks, including intended purpose, development processe, methods, and the elements of value (benefits and costs).

These resources could come in handy if you’re planning to attend the panel discussion, “Cancer Care Trends & the Future Directions.”

Real-World Evidence

NPC has a wide range of resources related to real-world evidence, from utilizing good methods and robustly assessing the evidence to communicating the information and applying it.

• Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue: NPC and AcademyHealth developed a conceptual framework to determine when different types of evidence (e.g., randomized controlled trials, pragmatic clinical trials, prospective registries, retrospective analyses) are “fit for purpose” for payer decision-making.
• When Does FDAMA Section 114 Apply? Ten Case Studies: NPC-funded research presents a set of case studies examining hypothetical promotions by biopharmaceutical companies and how they might be viewed under Section 114 of the Food and Drug Administration Modernization Act (FDAMA) of 1997.
• CER Collaborative Certificate Training Program: This online, 19-hour Accreditation Council for Pharmacy Education-approved practice certificate guides pharmacists and other clinical decision-makers on how to assess evidence from new, unfamiliar research designs (e.g., observational research methods, indirect treatment comparisons, modeling) to inform coverage decisions, while making use of the online Collaborative tool and resources.

Check out these resources if you’re focused on the panels “Real-World Evidence: What Does It Mean for Your Commercialization Plans?” or “Real-World Evidence & Patient Support Programs: A Perfect Marriage?”

Value-Based Insurance Design

NPC has conducted extensive research around value-based insurance design (VBID), which could be utilized to address concerns about access to high-value, specialty medications.

• Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design: This white paper highlights the importance of recognizing the value of specialty biopharmaceuticals through the use of VBID. The paper includes information on specific VBID techniques decision-makers should consider to support consumer access to specialty medications.

Download or pick up this resource if you’re attending the panel “Managing Specialty Pharmaceuticals: A Payer's Point of View.”

Risk-Sharing Agreements

Risk-sharing agreements between biopharmaceutical companies and payers offer potential benefits, including reducing payers’ risk of a sub-optimal purchase; earlier access to pharmaceuticals for patients and consumers; and more efficient pricing mechanisms. NPC research examines this payment model as it applies in the U.S.

• Private Sector Risk-Sharing Agreements in the U.S.: Trends, Barriers and Prospects: This peer-reviewed article presents a landscape assessment of risk-sharing agreements and identifies key issues impacting how successful they are in ensuring patient access to appropriate medications within the rapidly evolving health care financing system.

This resource is helpful if you’re going to the panels “Pharma Manufacturers' At-Risk Day is Coming Soon. Are You Ready?” or “Pharma’s Challenges to Limit High Drug Prices & Participate in Value Based Agreements.”

Accountable Care Organizations

Accountable care organizations (ACOs) have the potential to manage costs while providing high-quality care to patients. NPC’s research examines accountable care measures for specialty care and innovative treatments .

• Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment: This research sheds light on gaps in quality measurement and missed opportunities to promote improvement in patient care and health systems and also offers solutions for addressing measure gaps.
• Solutions for Filling Gaps in Accountable Care Measure Sets: This peer-reviewed research highlights where there are gaps in accountable care measure sets and that the gaps cannot be completely addressed with more of the same measure types and measurement strategies currently in use. Measurement enhancement suggestions are made that could include the increased use of outcome, cross-cutting, and patient-reported measures in measure sets, and new approaches to measurement including layered and modular models.
• Achieving Quality in ACOs: NPC created an easy-to-read infographic that explains what an ACO is and its potential for cost-savings.

These resources will be useful if you’re attending “Exploring the Impact of ACOs & Payment Reform on the Specialty Pharmacy Business Model.”

Throughout the Summit, find NPC at booth #633 to pick up our latest health policy research on these and other topics, and learn more about our activities by reading our 2015 Annual Report.